Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H26FN5O4S |
Molecular Weight | 559.611 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC=C1NC2=NN3C=C(C=CC3=N2)C4=CC=C(NC(=O)[C@H](C)C5=CC=C(F)C=C5)C=C4)S(C)(=O)=O
InChI
InChIKey=NRJKIOCCERLIDG-GOSISDBHSA-N
InChI=1S/C29H26FN5O4S/c1-18(19-4-9-22(30)10-5-19)28(36)31-23-11-6-20(7-12-23)21-8-15-27-33-29(34-35(27)17-21)32-25-14-13-24(40(3,37)38)16-26(25)39-2/h4-18H,1-3H3,(H,31,36)(H,32,34)/t18-/m1/s1
Molecular Formula | C29H26FN5O4S |
Molecular Weight | 559.611 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Empesertib (previously known as BAY-1161909) was developed as a selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase for the treatment of cancer. Empesertib participated in phase I clinical trials in combination with paclitaxel in subjects with advanced malignancies. The studies were terminated because another more successful Mps1 inhibitor was being developed in parallel.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P33981 Gene ID: 7272.0 Gene Symbol: TTK Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26832791 |
1.0 nM [IC50] | ||
Target ID: CHEMBL2637 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26832791 |
96.0 nM [Kd] | ||
Target ID: P45983|||Q308M2 Gene ID: 5599.0 Gene Symbol: MAPK8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26832791 |
240.0 nM [Kd] | ||
Target ID: P45984|||Q15711 Gene ID: 5601.0 Gene Symbol: MAPK9 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26832791 |
160.0 nM [Kd] | ||
Target ID: CHEMBL3983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26832791 |
0.34 nM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02138812
Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:40:46 UTC 2023
by
admin
on
Sat Dec 16 09:40:46 UTC 2023
|
Record UNII |
02Y3Z2756M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C61074
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
02Y3Z2756M
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
PRIMARY | |||
|
71599640
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
PRIMARY | |||
|
10550
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
PRIMARY | |||
|
C116074
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
PRIMARY | |||
|
1443763-60-7
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
PRIMARY | |||
|
CHEMBL3545425
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
PRIMARY | |||
|
300000034246
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
PRIMARY | |||
|
1443764-31-5
Created by
admin on Sat Dec 16 09:40:46 UTC 2023 , Edited by admin on Sat Dec 16 09:40:46 UTC 2023
|
NON-SPECIFIC STEREOCHEMISTRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|